PCSK9阻害

High BMI, High Benefit: How PCSK9 Inhibition Optimizes Outcomes in Obese Patients with ASCVD

A prespecified analysis of the FOURIER trial reveals that patients with obesity and atherosclerotic cardiovascular disease experience significantly higher absolute and relative risk reductions with evolocumab, particularly those with a BMI

Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial